ProMIS Neurosciences Inc. announced that its lead product candidate for Alzheimer's disease (AD), PMN310, showed absence of binding to amyloid beta (A) plaque in and around blood vessels in AD brain samples in a preclinical study directly comparing PMN310 to other A-directed antibodies. Binding of therapeutic antibodies to A deposits in brain tissue, in particular blood vessels, is believed to underlie the development of ARIA (amyloid-related imaging abnormalities; brain swelling and microhemorrhages) in treated AD patients. The binding profile of PMN310 in human AD brain tissue, as well as in brain samples from a mouse AD model, was directly compared to that of other A-directed antibodies in a preclinical study using the technique of immunohistochemistry (IHC). Results of the study showed binding of aducanumab and bapineuzumab to A plaque throughout the brain tissue, including in and around the blood vessels. Conversely, binding of PMN310 to A plaque was not observed in any region of the AD brain tissues.